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Abstract
Despite the dramatic success of combined antiretroviral therapies (cART) in controlling
peripheral  virus  replication,  the  prevalence  of  HIV‐1‐associated  neurocognitive
disorders (HAND) is on a rise as infected individuals continue to live longer. Almost
half of the infected individuals on ART develop HAND, out of which at least 30% suffer
from a comorbid condition of substance abuse. Involvement of autophagy has been
implicated not only in HIV‐1 infection of the CNS but also in CNS cells exposed to drugs
such as amphetamine, opiates, and cocaine, contributing in turn, to cellular dysfunction.
HIV‐1 is known to interfere with the autophagy pathway, resulting in turn to upregu‐
lation of HIV‐1 replication. Specifically, different HIV‐1 proteins such as TAT, gp120, and
Nef have been shown to act on various stages of autophagy such as initiation and
maturation and to affect overall autophagy levels. Whether or not abused drugs and
HIV‐1 can cooperate to dysregulate autophagy, however, remains unclear. This chapter
is focused on identifying the molecular mechanism(s) underlying HIV‐1 (proteins) and
cocaine, opiate, methamphetamine‐mediated impairment of autophagy. Such effects
could  underlie  the  synergistic  effects  of  HIV‐1  and  abused  drugs  in  exacerbating
symptoms of HAND.
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1. Introduction
Since the advent of combined antiretroviral therapy (cART), human immunodeficiency virus
(HIV‐1) infection has transformed into more manageable and controllable chronic disease
analogues to diabetes [1]. HIV‐1‐infected individuals on cART are living longer compared to
HIV‐1‐seronegative controls. Despite the dramatic success of cART in controlling viremia and
increased longevity, various comorbidities involving multiple organs including the brain are
on a rise in the infected individuals [2, 3]. In the context of CNS, there is an increased prevalence
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of HIV‐1‐associated neurocognitive disorders (HAND) due to the extended life expectancy.
HAND is composed of various entities of neurocognitive impairments ranging from asympto‐
matic to milder forms of motor disorders. Increased activation of microglia and astrocytes
(neuroinflammation) and synaptodendritic injury are the emerging hallmark features of HAND.
Although multiple factors and pathways have been proposed in the development of HAND,
the exact molecular mechanisms underlying the pathogenesis of HAND in the era of cART
remain elusive.
Autophagy is a highly conserved cellular process that is present in all eukaryotic cells.
Autophagy allows the orderly degradation and recycling of cellular components [4]. During
this process, targeted cytoplasmic constituents are isolated from the rest of the cell within a
double‐membraned vesicle known as the autophagosome. The autophagosome fuses with a
lysosome and the contents are degraded and recycled. Autophagy can be broadly divided into
several stages: initiation, elongation, autophagosome formation, and maturation. Each stage
is tightly and sequentially regulated by multiple autophagy‐related proteins, to ensure the
completion of whole process (autophagy flux).
It is well recognized that drug abuse serves as a significant risk factor for acquiring HIV‐1
infection and has been implicated in worsening the symptoms of HAND [5, 6]. HIV‐1‐positive
individuals with a history of abused drug exposure exhibit severe cognitive and behavioral
dysfunction compared to those without exposure to abused drugs. Clinical evidence points to
increased neuroinflammation, severe neuronal injury, and increased viral loads in the brains
of HIV‐1‐positive patients with a history of drug addiction compared to the brains of infected
individuals that were drug naive [5, 6]. Abused drugs including cocaine, methamphetamine,
and opiates have been shown to interact with the autophagy pathway in various kinds of cells
including microglia, astrocytes, and neurons to alter their homeostasis. Dysfunction of these
three cell types plays critical roles in the pathogenesis of HAND.
In this chapter, we focus on the intermingled relationship between HIV‐1, abused drugs, and
autophagy. HIV‐1/HIV‐1 proteins and drugs of abuse, that have been shown to interact with
various stages of autophagy pathway, can synergistically lead to autophagy dysregulation,
which, in turn, contributes to accelerated pathogenesis of HAND. Understanding and
clarification of the complex interplay of HIV‐1, abused drugs and HAND could set a stage for
future development of novel target(s) as alternative therapeutic approaches to ameliorate
HAND in HIV‐1‐infected individuals on cART.
2. HIV‐1, HAND, and cART
In 1983, HIV‐1 was first isolated and identified as a lentivirus (a subgroup of retrovirus) that
was the causative agent for acquired immune deficiency syndrome (AIDS). In the pre‐
antiretroviral therapy era, the average survival time following infection with HIV‐1 was
estimated to be 9–11 years, depending on the HIV‐1 subtype [7]. In 1996, the introduction of
combined antiretroviral therapy (cART) changed the course of the HIV‐1 epidemic. In the
current era of cART, HIV‐1 infection has become a more controllable and manageable disease,
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with increased patient longevity [1, 8]. Clinical studies have shown that in patients with well‐
controlled viremia, the CD4 numbers are relatively maintained in a normal range (400–
1600/mm3) and also that the function of immune system is well preserved with extended
periods of undetectable viral loads.
HAND is composed of neurological complications that range from asymptomatic neurocog‐
nitive impairment (ANI) to milder forms of cognitive impairment (MNI). While severe
complications of CNS such as HIV‐associated dementia (HAD) have declined in the post‐cART
era, emergence of milder cognitive motor disorders is actually on rise. In fact, as HIV‐1‐infected
individuals continue to live longer lives, it is estimated that up to 50% of those individuals still
continue to display varying degrees of neurocognitive impairment, which could impact their
quality of life, leading to increased healthcare burden.
Various theories are extant about the mediators that regulate pathogenesis of HAND. For
example, it has been implicated that direct injury caused by HIV‐1 and its associated proteins
such as the envelope gp120, transactivator of transcription (TAT), and Vpr can mediate damage
in the CNS. Furthermore, indirect damage caused by proinflammatory cytokines/chemokines
and chronic, sustained immune activation in the CNS can all play key roles in the pathogenesis
and progression of HAND [9, 10]. It is now well accepted that events secondary to HIV‐1
infection (inflammation) are critical for CNS damage associated with HAND [10]. Other factors
have also been shown to contribute to HAND development. For example, factors such as
inefficient CNS penetration of cART and/or emergence of latent virus reservoirs can also be
attributable factors to the pathogenesis of HAND [11, 12]. Additionally, it is now becoming
well recognized that HAND is prevalent in infected individuals abusing recreational drugs.
In fact, substance abuse and co‐infection with hepatitis C are recognized comorbidities of HIV
infection. In summary, while treatment with cART has reduced the incidence of the severe
form of CNS impairment such as HAD, low‐level ongoing inflammation in the periphery and
in the CNS and HAND is emerging as newer comorbidity of HIV infection.
3. HIV‐1 and autophagy
Autophagy and the innate immune responses are highly conserved evolutionarily processes
in virtually all the eukaryotic cells [4]. Autophagy is an important player in various diseases
such as cancer and neurodegenerative disorders [4]. At the cellular level, HIV‐1 can infect
dendritic cells (DC), monocytes, and CD4+ T cells in the periphery and microglia and astrocytes
(limited infection) in the CNS. Depending on the cell type, HIV‐1 can either usurp certain
autophagy‐related proteins or block autophagy flux to invade the host immune response,
thereby exacerbating HIV‐1 replication and transmission [13].
In DCs, HIV‐1 impairs autophagy to subvert host immunity and enhance trans‐infection. The
efficiency of DCs being infected by HIV‐1 heavily depends on their origin and activation state
[14]. Previous reports have demonstrated that immature, resting DCs are more readily infected
with HIV‐1 than mature, activated DCs that are induced either by TNF‐α or by poly I:C [14,
15]. Of note, while immature DCs seem to be more easily infected with HIV‐1, mature DCs are
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more efficient at mediating trans‐infection to CD4+ T cells without themselves getting infected
[14]. The idea that autophagy is a mechanism that protects against HIV‐1 infection originated
from the fact that treatment of DCs with either TNF‐α or poly (I:C) led to the activation and
upregulation of autophagy suggests thereby that elevated levels of autophagy degrade the
incoming virions in mature DCs [15]. Another study indicated that viral Env downregulated
autophagy through mTOR activation, thereby protecting the virus from autophagy‐mediated
degradation, ultimately leading to increased trans‐infection to CD4+ T cells [16]. These results
reveal a mechanism by which HIV‐1 limits autophagy in DCs to target immune function
leading, in turn, to increased transmission.
HIV‐1 is known to infect macrophages, without a negligible change in cell numbers [17]. The
role of autophagy in viral replication in the macrophages, however, remains poorly explored.
In one study, it was shown that autophagic vacuoles were increased in infected macrophages.
The mechanism underlying this phenomenon involved inhibition of the maturation stage of
autophagy by HIV‐1 factor Nef, via its association with the autophagy regulator Beclin‐1 [18].
Thus, HIV‐1 can exploit early stages of autophagic signaling in the macrophages for biogenesis
and egress, while concomitantly also inhibiting the maturation stages of autophagy to prevent
its own degradation. One of the key hallmark features of HIV‐1 infection is a significant
depletion of CD4+ T cell in patients that are treatment naive [19, 20]. Previous investigations
have addressed the effects of HIV‐1 protein Env on bystander T‐cell death [20]. Although
autophagic vacuoles (AV) were increased in these bystander T cells, the exact role of autophagy
contributing to cell death still remains elusive. Since the autophagic process involves the
capture and degradation of activated inflammasome complexes, increased numbers of AV in
the bystander CD4+ T cells could thus imply an attempt by the cell to upregulate autophagy
as part of an anti‐inflammatory response. The failure of autophagy to protect these bystander
cells from inflammasome activation could eventually lead to cell death. Thus, while autophagy
has no direct role in CD4+ T‐cell death, it can be envisioned as a secondary, compensatory
mechanism that is an attempt at salvaging the cells from apoptosis [21].
Microglia is the primary immune‐competent cells of the brain. Similar to peripheral immune
cells, HIV‐1 and viral proteins also modulate autophagy levels in microglia. A recent study has
demonstrated that expression levels of autophagy markers such as Beclin‐1, ATG5, LC3‐II, and
p62 were significantly altered in microglia from HIV‐1‐infected individuals with NCI ± HIV‐1
encephalitis (HIVE) [22]. Autophagy dysregulation could thus be associated with the micro‐
glial activation status. Another investigation provided a more direct evidence focusing on the
role of HIV‐1 infection on microglial autophagy [23]. In this study, it was shown that in primary
human microglia infected with macrophage‐tropic HIV‐1SF162 strain, there was increased
protein expression of Beclin‐1 and LC3‐II. In these infected cells, accumulation of LC3 report‐
er RFP+ GFP+ (yellow) puncta suggested that HIV‐1 infection triggered autophagosome
formation without promoting protein degradation by the lysosomes. These findings imply that
HIV‐1 can usurp autophagy pathway to promote its own replication. Increasing autophagy
flux could thus serve as a potential therapeutic approach against HIV‐1 infection in microglia.
Similar to microglia, dysregulation of autophagy in HIV‐1‐infected astrocytes has also been
reported [24].
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Unlike the microglia and astrocytes, HIV‐1 does not infect the neurons, primarily due to lack
of CD4+ receptor in these latter cells. Neurons, however, are susceptible to the toxic effects of
HIV‐1 proteins TAT and gp120, which have been shown to dysregulate autophagy, leading, in
turn, to neurotoxicity and/or neuronal injury including synaptodendritic injury. A seminal
report [25] investigated the role of autophagy in microglia‐induced neurotoxicity in primary
rodent neurons. These authors demonstrated that conditioned media from simian immuno‐
deficiency virus (SIV)‐infected microglia inhibited autophagy in rodent neurons, leading to
decreased neuronal survival. It is likely that a combination of HIV‐1 proteins (TAT/gp120) and/
or multiple inflammatory mediators released from the infected cells could be contributing to
the dysregulation of autophagy. Another study has provided evidence that HIV‐1 protein TAT
can impair the endolysosome structure and function and ensuing autophagy in the neurons
[26]. In this study, it was shown that following the treatment of primary cultured rat hippo‐
campal neurons with HIV‐1 TAT, neuronal viability was significantly decreased. The authors
reported significant changes in the structure and membrane integrity of endolysosomes,
endolysosome pH, and autophagy flux, which were responsible for neuronal death. In
agreement with these findings, report by Fields et al. also demonstrated that TAT altered
neuronal autophagy by modulating autophagosome fusion to the lysosome [27]. In this study,
TAT exposure resulted in increased numbers of LC3‐II puncta and autophagosomes in a
neuronal‐derived cell line in vitro. Similarly, in vivo studies in GFAP‐TAT transgenic mice
showed increased autophagosome accumulation in the neurons that was accompanied with
altered LC3‐II levels and neuron dysfunction. The findings from this study implicate that
therapies targeting TAT‐mediated autophagy alterations could mitigate neurodegeneration in
HIV‐1‐infected individuals with HAND.
4. Cocaine, HIV‐1, and autophagy
Cocaine, one of most abused drugs, is known to lead to drug addiction. At the molecular level,
cocaine binds to dopamine transporter to block dopamine uptake by the neurons, leading
subsequently to elevated synaptic dopamine concentrations. Increased synaptic dopamine
levels can, in turn, overstimulate the dopamine receptors located in the post‐synaptic mem‐
brane resulting in enhanced neuronal excitability in the brain striatum [28]. Emerging evidence
also demonstrates that cocaine‐mediated microglial activation can contribute to the develop‐
ment of drug addiction [29]. In this study, it was shown that cocaine directly interacts with the
Toll‐like receptor 4‐mediated pathway to activate microglia, resulting in enhanced microglial‐
neuronal cross talk and enhanced synaptic dopamine concentrations. Inhibition of microglial
activation through pharmacological or genetic approaches was shown to block cocaine‐
mediated reward‐related behavioral changes.
Compared to other abused drugs such as methamphetamine and morphine that have been
implicated to dysregulate autophagy, reports on cocaine‐mediated induction of autophagy in
cells of the CNS are relatively scant. In a recent study, it was shown that [30] cocaine exposure
resulted in induction of autophagy both in microglia and in astrocytes and also in vivo in mice
administered cocaine. Cocaine exposure can lead to increased expression of various autophagy
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markers such as Beclin‐1, ATG5, and LC3‐II in both a dose‐ and time‐dependent manner. In
this study, upstream activation of ER stress was shown to mediate induction of autophagy. It
was shown that increased autophagy contributed to cocaine‐mediated activation of microglia
since pre‐treatment of cells with wortmannin resulted in decreased expression and release of
inflammatory factors (TNF‐α, IL‐1β, IL‐6, and CCL2). In another report, it was demonstrated
that cocaine induced autophagic death in astrocytes, a process involving activation of sigma
1 receptor, PI3K, and mTOR pathway [31]. In another recent report, cocaine exposure of
neurons was also shown to elicit autophagic cytotoxicity via a nitric oxide‐GAPDH signaling
cascade [32]. In this study, cocaine exposure markedly increased levels of LC3‐II with a
concomitant depletion of p62. Pharmacologic inhibition of autophagy protected neurons
against cocaine‐induced cell death.
Cocaine abuse is one of the comorbidities of HIV‐1 infection. Cocaine abuse has been demon‐
strated to increase HIV‐1 infection rate and to accelerate HAND pathogenesis [33, 34]. HIV‐1‐
infected individuals abusing cocaine exhibited increased virus loads in the brain with
associated neuroinflammation and neuronal injury compared to HIV‐1‐infected individuals
that were drug naïve. Clinical evidence showed that cocaine use resulted in lack of virologic
suppression and accelerated decline of CD4+ T cells even among ART‐adherent patients [35]
which was consistent with findings that cocaine enhanced HIV‐1 replication, as demonstrated
in multiple in vitro and in vivo studies [36, 37]. In addition to its effects on virus replication,
cocaine has also been shown to disrupt the integrity of brain‐blood barrier, resulting in
enhanced macrophage/monocyte influx into the brain, leading to increased neuroinflamma‐
tion [38]. Additionally, cocaine has also been shown to potentiate toxicity of HIV‐1 proteins
such as gp120 in the brain [39]. Similar to gp120, cocaine and TAT exerted a synergistic
neurotoxic effect in rat primary hippocampal neurons [40]. In these cells, cocaine exposure
exacerbated TAT‐induced mitochondrial depolarization and generation of intracellular ROS
[40]. Cocaine can thus modulate the activation status of microglia and astrocytes through
multiple mechanisms including ROS, ER stress, and autophagic pathways [30, 41].
5. Methamphetamine (METH), HIV‐1, and autophagy
METH is a psychostimulant drug which is extensively abused for its stimulant, euphoric,
empathogenic, and hallucinogenic properties [42]. METH predominantly disrupts the
monoamine neurotransmitter system of the brain leading to persistent damage in the serotonin
and dopamine neurotransmission, a mechanism also accountable for the motor deficiencies
observed in Parkinson's disease [43]. While METH‐mediated impairment in neurotransmis‐
sion results in nigrostriatal denervation, accumulation of ubiquitin‐positive neuronal inclu‐
sions, and striatal dopamine loss resulting in long‐term neurotoxicity [42], METH does not
affect dopaminergic neurons in the substantia nigra pars compacta. Although nigral cell bodies
are largely preserved following exposure to METH, cytoplasmic features do reveal the
presence of autophagic‐like vacuolization and accumulation of α‐synuclein, ubiquitin, and
parkin‐positive inclusion‐like bodies [44], as is the feature of several neurodegenerative
diseases [45]. Chronic use of METH is closely coupled with cognitive deficits ranging from
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impaired impulse control, attentional problems, working memory, and decision making to
motor coordination, including inhibitory control [46]. Apart from this, chronic METH abuse
also leads to a limited, but persistent, loss of dopamine and serotonin transporters in the
striatum, cortex, and hippocampal areas. METH abuse also induces basal ganglia‐mediated
behavioral deficits, which is secondary to compromised dopamine neurotransmission in the
moderately denervated striatum [47].
Emerging studies also correlate the use of METH with the activation of autophagy in both the
CNS and periphery [48]. The effects of METH on the autophagic pathway are likely to depend
on the superfluous free radicals and oxidative species generated within the cells. These effects
become predominant within the dopaminergic neurons, which is likely due to the specificity
of METH for dopamine targets and the ability of dopamine to self‐oxidize and produce free
radicals [49]. Indeed, the mechanisms of action of METH involve release of cytosolic dopamine
and are based on various molecular targets such as the dopamine transporter, the vesicular
monoamine transporter‐2, and monoamine oxidase, which are involved in the uptake, storage,
and release of dopamine [50]. By acting on the dopamine vesicular storage, METH interrupts
the physiological gradient, with the diffusion of large amount of dopamine into the cytosol,
where the blockage of monoamine oxidase type A abrogates its physiological metabolism,
leaving the cytosolic dopamine vulnerable to self‐oxidize to form dopamine‐quinones and
cysteinyl aggregates, thereby promoting neurotoxicity [49].
In addition to its direct neurotoxic effects, the dysfunction of blood‐brain barrier (BBB) is also
a feature of METH‐induced neurotoxicity [51]. METH has been shown to induce the impair‐
ment of GLUT1 at the brain endothelium thereby contributing the energy‐associated disrup‐
tion of tight junction assembly and loss of BBB integrity [52]. Moreover, METH acts directly
on cultured rat brain microvascular endothelial cells to compromise the BBB via the involve‐
ment of eNOS/NO‐mediated transcytosis [51]. Additionally, METH mediates a transient
increase in the permeability of the BBB in the hippocampus compared with the frontal cortex
and striatum, via alterations in the expression levels of tight junction proteins and matrix
metalloproteinase‐9 [53]. Low doses of METH (1 μM) have been shown to induce endothelial
cell barrier dysfunction, thereby underscoring the role of METH in BBB compromise [51].
Interestingly, exposure of low doses of METH also induces induction of autophagy in two
dopaminergic neuronal‐derived cell lines such as the rat pheochromocytoma PC12 and the
human neuroblastoma SH‐SY5Y through the phosphatidylinositide 3‐kinase III signaling. In
contrast, caspase‐dependent neuronal cell death involves inhibition of the autophagy matu‐
ration process despite the aggregation of α‐synuclein and damaged mitochondria in the
cytoplasm of METH‐exposed cells [44]. Similarly, METH exposure also leads to the induction
of the autophagic sequestering process (by inducing LC3‐II expression) in human dopami‐
nergic SK‐N‐SH cell line by ameliorating the mTOR activity on its downstream phosphoryla‐
tion of the target eukaryotic translation initiation factor 4E‐binding protein 1, eventually
resulting in decreased cell viability [54]. METH exposure of SK‐N‐SH cells also induces
autophagy by blocking both the dissociation of the Bcl‐2/Beclin‐1 complex and upstream
activation of c‐Jun N‐terminal kinase 1 signaling [55]. Acute METH exposure also has been
shown to induce autophagy as an early protective response. Chronic METH exposure on the
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other hand exacerbates the progression of autophagic flux leading, in turn, to apoptotic cell
death in primary human brain microvascular endothelial cells and human umbilical vein
endothelial cells, through the Kappa opioid receptor [56]. Recent investigations have also
identified the potentiation of METH‐mediated neurotoxicity by caffeine through inhibition of
autophagy via the protein kinase A activation pathway and via enhancement of LC3‐II
phosphorylation, thereby abrogating incorporation of LC3‐II into the autophagosomes [57]. In
cardiomyocytes and dopaminergic neurons, METH exposure also stimulates the damage‐
inducible transcript 4 expression leading to induction of autophagy and apoptosis [58, 59].
METH use has been associated with higher risk‐taking behaviors that set drug abusers at a
higher risk of exposure to infections such as HIV‐1 and hepatitis C, each, in turn, contributing
eventually to CNS dysfunction. METH abuse has also been shown to accelerate the onset and
severity of HAND. Neurotoxic consequences of METH abuse and HIV‐1 infection include brain
hyperthermia, release of inflammatory cytokines and reactive oxygen species, excitotoxicity,
and astrogliosis [60]. METH abuse in combination with HIV‐1 infection leads to notable
variations in the functioning of dopaminergic neurons. Role of HIV‐1 TAT protein that is
actively released by infected glial and lymphoid cells has been well documented in the
pathogenesis of HAND [61–63]. Intrastriatal administrations of HIV‐1 TAT combined with
gp120 protein have been shown to damage both efferent and afferent neurons in the striatum
[64], including the nigrostriatal DA neurons [65], likely underlie the motor abnormalities
observed in HIV‐1‐infected individuals. Co‐exposure of HIV‐1 TAT and METH cross‐amplifies
their deleterious cellular effects through oxidative stress‐mediated inflammatory mediators
such as TNF‐α, IL‐β, and ICAM‐1 in distinct regions of the mice brain, with implications for
CNS complications in HIV‐1‐infected individuals abusing drugs. Additionally, mice adminis‐
tered HIV‐1 TAT and METH were shown to exhibit enhanced DNA‐binding activities of
transcription factors such as NF‐kB, AP‐1, and CREB in the frontal cortex and hippocampal
regions compared with mice administered either HIV‐1 TAT or METH alone [60]. These
findings likely suggest that HIV‐1 TAT and METH synergistically decrease striatal dopamine
release and content, which likely leads to increased risk for basal ganglia dysfunction and
cognitive impairment in METH abusers that are infected with HIV‐1 [66].
Interestingly, METH abuse is closely associated with higher viral loads in ART‐receiving HIV‐
1‐positive individuals [67]. The combination of METH and HIV‐1 leads to increased neuro‐
cognitive deficits and neuropathology compared with the either agent alone [68]. The potential
mechanistic interactions of virus, antiviral treatment, and the psychostimulant drug, however,
remain largely unknown. Furthermore, METH‐mediated dopamine accumulation in the
synapse also increases the levels of free radicals in the neurons, thereby promoting protein
damage as well as protein dysfunction, leading to upregulation of autophagy [48]. It has also
been shown that exposure of neurons to varying combinations of cART and METH, along with
HIV‐1‐envelope gp120, compromised cellular ATP homeostasis in association with activation
of both AMP‐activated protein kinase (AMPK) and autophagy [68]. Overall, METH‐mediated
neurotoxicity is mediated by induction of a specific cellular pathway that is activated when
dopamine is not effectively sequestered in the synaptic vesicles, thereby producing oxidative
stress, autophagy, and eventually neurite degeneration.
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6. Morphine, HIV‐1, and autophagy
Opiates are the most potent and popular compounds known to control pain and are also among
the most common drugs of abuse. Heroin is one such highly addictive, illegal opioid drug.
Since heroin is converted to morphine in the brain, morphine has been the preferred opiate of
choice in most studies. Morphine is a natural opiate that has a clinically widespread use for
pain management in cancer patients. Despite its beneficial effects, chronic use of opiates elicits
adverse side effects, such as memory impairment, tolerance, dependence, drug addiction, and
neural injury [69]. Morphine exposure also significantly alters the immune system by modi‐
fying the functions of a range of immune cells such as phagocytes, T cells, and dendritic cells
[70, 71]. Morphine induces cellular impairment via inhibition of the central cholinergic system,
altered expression of μ‐opioid receptor, attenuation of long‐term potentiation in the hippo‐
campus caused by accumulation of extracellular adenosine [72], increased glucocorticoid
concentration in plasma [73], and inhibition of nitric oxide synthesis in the brain [74].
Morphine induces autophagy through sustained activation of μ‐opioid receptor in rat
hippocampal neurons and in neuroblastoma SH‐SY5Y cells resulting in neuronal injury [75].
Morphine‐mediated induction of autophagy in these cells is operated primarily by PTX‐
sensitive G protein‐coupled receptor signaling. Following its binding to μ‐opioid receptor,
there is an increase in Beclin‐1 protein levels and a significant decrease in the association of
Beclin‐1 with Bcl‐2 leading, in turn, to dissociation of Beclin‐1 from its pro‐autophagic events.
It has been reported that Bcl‐2 overexpression remarkably impedes morphine‐mediated
autophagy induction and that genetic silencing of Beclin‐1 or another autophagy marker ATG5
inhibits morphine‐mediated autophagy. Long‐term exposure of morphine has been shown to
stimulate neuronal cell death, an effect that is exacerbated by genetic silencing of Beclin‐1.
Taken together, this study for the first time identified key roles of Beclin‐1 and ATG5 in
morphine‐mediated induction of neuronal injury [75].
In another study, long‐term morphine exposure was shown to induce autophagy in the
superficial layer of the spinal cord through upregulation of Beclin‐1, LC3‐II, and cathepsin B
in the GABAergic interneurons, resulting in the development of antinociceptive tolerance.
Blockade of either cathepsin B or autophagy notably suppressed morphine‐mediated antino‐
ciceptive tolerance [76]. Morphine abuse was also closely associated with decreased mito‐
chondrial DNA copy number both in the hippocampus and in peripheral blood and was linked
to drug addiction. These findings were also corroborated in heroin addicts [77]. Morphine
exposure also has been shown to potentiate LPS‐induced autophagy initiation and block the
fusion of autophagosomes in macrophages, leading to defective bacterial clearance and
increased bacterial load via TLR4‐dependent and TLR4‐independent pathways. Morphine
exposure thus increases the susceptibility to infection as well as prevalence of persistent
infection in drug addicts [78]. Morphine also increases autophagic flux both in the hippocam‐
pal CA1 neurons and in microglia, leading to increased neuronal cell death in the CA1 and
CA3 regions and escalated inflammation in the hippocampal microglia, ultimately resulting
in morphine‐mediated spatial memory impairment [79].
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Opiates abuse and HIV‐1 are interlinked epidemics, and opiates such as heroin exacerbate the
neuropathogenesis of HIV‐1 with rapid disease progression [80]. Long‐term opiate abuse in
the pre‐cART era was demonstrated to be directly associated with increased progression to
HIVE and exacerbated neuropathology in patients on cART [81]. Morphine exacerbates HIV‐
1 toxicity through distinct pathways in neurons and in glia, primarily through the μ‐opioid
receptors. Acute exposure of morphine leads to increased HIV‐1 replication in the infected
microglia [82]. Morphine potentiates the deleterious effects of HIV‐1 TAT via dysregulation of
intracellular calcium homeostasis, leading to decreased buffering of extracellular glutamate in
the astrocytes. This dysfunction in turn leads to decreased excitotoxicity threshold of neurons,
resulting in increased production of reactive species and proinflammatory mediators, which
ultimately damage the neurons [83]. Morphine exposure has also been shown to enhance both
HIV‐1 replication and inflammatory response through the Beclin‐1‐independent mechanism
in microglial cells, implicating the connections between autophagy and HIV‐1 pathogenesis
[23]. In another study, chronic morphine exposure of HIV‐1‐infected human monocyte‐derived
macrophages led to significant alterations in the secretion of IL‐6 and monocyte chemoattrac‐
tant protein 2, thereby suggesting enhanced CNS inflammation in HIV‐1‐infected opiate
abusers [84].
7. Conclusion
Overall, this chapter sheds light on HIV‐1, drugs of abuse such as cocaine, methamphetamine,
and morphine‐mediated autophagy primarily in the CNS and periphery. Such effects could
underlie the synergistic effects of HIV‐1 and abused drugs in exacerbating symptoms of
HAND. Further studies, however, are warranted to unravel the mechanistic roles of autophagy
in CNS cells and periphery in HIV‐1‐infected individuals with a history of drug addiction.
Primarily, how autophagy might be involved in these cells and its relative contribution to
immunopathogenesis, particularly HAND, has yet to be determined. Investigating autophagy
in various cell types involved in the pathogenesis of HIV‐1 infection in the context of drug
abuse could provide a basis for future development of novel therapeutic strategies aimed at
treating HIV‐1‐infected individuals that abuse drugs.
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